Saturday 17 October 2026
Export CBLL’s income statement to Excel — free account
CeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024. In the quarter to June 2026, revenue grew 32.5%, EPS fell 34.2%, free cash flow fell 68.6% and total debt rose 1.52%, each against the same quarter a year earlier.
25.04
2.60
−9.41%
Follow CBLL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
7.25 | 7.26 | 9.00 | 5.11 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(57.51) | (35.78) | (74.38) | (38.11) | |
P/B ratio |
5.77 | 4.90 | 5.16 | 2.58 | |
Price to Tangible BV |
5.77 | 4.90 | 5.16 | 2.58 | |
EV/Sales |
6.18 | 5.99 | 7.43 | 3.31 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.67) | (11.69) | (16.22) | (6.85) | |
EV/FCF |
(11.24) | (11.21) | (15.64) | (6.61) | |
Quick Ratio |
8.45 | 9.69 | 9.08 | 11.92 | |
Current Ratio |
9.18 | 10.44 | 9.73 | 12.65 | |
Net Debt/EBITDA |
5.39 | 5.76 | 9.41 | 9.89 | |
Debt/Assets |
12.01% | 11.18% | 10.12% | 9.90% | |
Debt/Equity |
0.16 | 0.14 | 0.13 | 0.12 | |
Asset Turnover |
0.55 | 0.49 | 0.42 | 0.67 | |
Operating CF/Net income |
0.67 | 0.98 | 0.80 | 0.82 | |
Capex/Depreciation |
0.76 | 2.57 | 2.46 | 1.14 | |
Interest Coverage |
(45.62) | (47.80) | (31.59) | (30.51) | |
Research and Development Expense of Revenue |
24.01% | 23.25% | 20.42% | 22.06% | |
Selling, General and Administrative Expense of Revenue |
139.42% | 142.32% | 125.79% | 131.06% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
21.35% | 14.05% | 13.55% | 14.83% | |
Graham Net Nets |
0.16 | 0.19 | 0.18 | 0.37 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.05%) | (8.89%) | (6.70%) | (13.14%) | |
Free Cash Flow Yield |
(7.58%) | (7.35%) | (5.28%) | (9.81%) | |
Revenue per Share |
0.74 | 0.70 | 0.68 | 0.61 | |
Operating CF per Share |
(0.34) | (0.51) | (0.29) | (0.30) | |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.34) | (0.53) | (0.31) | (0.31) | |
Cash per Share |
3.40 | 3.75 | 4.36 | 4.58 | |
Shareholders Equity per Share |
3.37 | 3.74 | 4.25 | 4.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.37 | 3.74 | 4.25 | 4.46 | |
Free Cash Flow |
(13.09) | (20.12) | (11.33) | (11.56) | |
Working Capital |
140.65 | 152.73 | 167.53 | 176.64 | |
Capital Expenditures |
(0.22) | (0.83) | (0.55) | (0.46) | |
Net Current Asset Value |
119.81 | 131.65 | 146.25 | 156.36 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.03 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.15 | 13.51 | 12.97 | 11.10 | |
Average Payables |
2.81 | 1.68 | 1.99 | 2.48 | |
Average Inventory |
6.37 | 6.73 | 7.11 | 6.47 | |
Average Assets |
187.02 | 195.77 | 210.61 | 123.29 | |
Average Common Equity |
150.23 | 160.85 | 173.25 | 14.05 |
Columns are period end dates